AstraZeneca’s Tozorakimab Has Already Won the COPD Biologic Race — The Market Just Doesn’t Know It Yet
AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...
COPD
AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...